Skip to main content
Top
Published in: Cancer Causes & Control 4/2010

01-04-2010 | Brief report

The impact of delayed blood centrifuging, choice of collection tube, and type of assay on 25-hydroxyvitamin D concentrations

Authors: Chu-Ling Yu, Roni T. Falk, Michael G. Kimlin, Preetha Rajaraman, Alice J. Sigurdson, Ronald L. Horst, Louis M. Cosentino, Martha S. Linet, D. Michal Freedman

Published in: Cancer Causes & Control | Issue 4/2010

Login to get access

Abstract

Studies have examined the associations between cancers and circulating 25-hydroxyvitamin D [25(OH)D], but little is known about the impact of different laboratory practices on 25(OH)D concentrations. We examined the potential impact of delayed blood centrifuging, choice of collection tube, and type of assay on 25(OH)D concentrations. Blood samples from 20 healthy volunteers underwent alternative laboratory procedures: four centrifuging times (2, 24, 72, and 96 h after blood draw); three types of collection tubes (red top serum tube, two different plasma anticoagulant tubes containing heparin or EDTA); and two types of assays (DiaSorin radioimmunoassay [RIA] and chemiluminescence immunoassay [CLIA/LIAISON®]). Log-transformed 25(OH)D concentrations were analyzed using the generalized estimating equations (GEE) linear regression models. We found no difference in 25(OH)D concentrations by centrifuging times or type of assay. There was some indication of a difference in 25(OH)D concentrations by tube type in CLIA/LIAISON®-assayed samples, with concentrations in heparinized plasma (geometric mean, 16.1 ng ml−1) higher than those in serum (geometric mean, 15.3 ng ml−1) (p = 0.01), but the difference was significant only after substantial centrifuging delays (96 h). Our study suggests no necessity for requiring immediate processing of blood samples after collection or for the choice of a tube type or assay.
Literature
1.
go back to reference Bertone-Johnson ER, Chen WY, Holick MF et al (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14:1991–1997CrossRefPubMed Bertone-Johnson ER, Chen WY, Holick MF et al (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14:1991–1997CrossRefPubMed
2.
go back to reference Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16:83–95CrossRefPubMed Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16:83–95CrossRefPubMed
3.
go back to reference Giovannucci E (2009) Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 19:84–88CrossRefPubMed Giovannucci E (2009) Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 19:84–88CrossRefPubMed
4.
go back to reference Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459PubMedCrossRef Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459PubMedCrossRef
5.
go back to reference Ahn J, Peters U, Albanes D et al (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100:796–804CrossRefPubMed Ahn J, Peters U, Albanes D et al (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100:796–804CrossRefPubMed
6.
go back to reference Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA (2007) Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 16:2784–2786CrossRefPubMed Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA (2007) Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 16:2784–2786CrossRefPubMed
7.
go back to reference Freedman DM, Looker AC, Chang SC, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–1602CrossRefPubMed Freedman DM, Looker AC, Chang SC, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–1602CrossRefPubMed
8.
go back to reference Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE (2007) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 16:783–788CrossRefPubMed Tworoger SS, Lee IM, Buring JE, Rosner B, Hollis BW, Hankinson SE (2007) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev 16:783–788CrossRefPubMed
9.
go back to reference Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15:255–265CrossRefPubMed Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15:255–265CrossRefPubMed
10.
go back to reference Landi MT, Caporaso N (1997) Sample collection, processing and storage. IARC Sci Publ 142:223–236PubMed Landi MT, Caporaso N (1997) Sample collection, processing and storage. IARC Sci Publ 142:223–236PubMed
11.
go back to reference Tworoger SS, Hankinson SE (2006) Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol Biomarkers Prev 15:1578–1581CrossRefPubMed Tworoger SS, Hankinson SE (2006) Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol Biomarkers Prev 15:1578–1581CrossRefPubMed
12.
go back to reference Binkley N, Krueger D, Gemar D, Drezner MK (2008) Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93:1804–1808CrossRefPubMed Binkley N, Krueger D, Gemar D, Drezner MK (2008) Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93:1804–1808CrossRefPubMed
13.
go back to reference Hollis BW, Horst RL (2007) The assessment of circulating 25(OH)D and 1,25(OH)2D: where we are and where we are going. J Steroid Biochem Mol Biol 103:473–476CrossRefPubMed Hollis BW, Horst RL (2007) The assessment of circulating 25(OH)D and 1,25(OH)2D: where we are and where we are going. J Steroid Biochem Mol Biol 103:473–476CrossRefPubMed
14.
go back to reference Ersfeld DL, Rao DS, Body JJ et al (2004) Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 37:867–874CrossRefPubMed Ersfeld DL, Rao DS, Body JJ et al (2004) Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 37:867–874CrossRefPubMed
15.
go back to reference Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL (1993) Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 39:529–533PubMed Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL (1993) Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 39:529–533PubMed
16.
go back to reference Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121–130CrossRefPubMed Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121–130CrossRefPubMed
18.
go back to reference Lissner D, Mason RS, Posen S (1981) Stability of vitamin D metabolites in human blood serum and plasma. Clin Chem 27:773–774PubMed Lissner D, Mason RS, Posen S (1981) Stability of vitamin D metabolites in human blood serum and plasma. Clin Chem 27:773–774PubMed
19.
go back to reference Mason RS, Posen S (1977) Some problems associated with assay of 25-hydroxycalciferol in human serum. Clin Chem 23:806–810PubMed Mason RS, Posen S (1977) Some problems associated with assay of 25-hydroxycalciferol in human serum. Clin Chem 23:806–810PubMed
20.
go back to reference Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier C (2005) Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 51:395–400CrossRefPubMed Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier C (2005) Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 51:395–400CrossRefPubMed
21.
go back to reference Wagner D, Hanwell HE, Vieth R (2009) An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem 42:1549–1556CrossRefPubMed Wagner D, Hanwell HE, Vieth R (2009) An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem 42:1549–1556CrossRefPubMed
22.
go back to reference Heaney RP (2005) The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 97:13–19CrossRefPubMed Heaney RP (2005) The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 97:13–19CrossRefPubMed
Metadata
Title
The impact of delayed blood centrifuging, choice of collection tube, and type of assay on 25-hydroxyvitamin D concentrations
Authors
Chu-Ling Yu
Roni T. Falk
Michael G. Kimlin
Preetha Rajaraman
Alice J. Sigurdson
Ronald L. Horst
Louis M. Cosentino
Martha S. Linet
D. Michal Freedman
Publication date
01-04-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 4/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-009-9485-x

Other articles of this Issue 4/2010

Cancer Causes & Control 4/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine